Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 12/20 | 0.60 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532954 | 0.84 | PARP1 (0.48) | PARP1SMYD3PDE3BPDE3A | |
| SCHEMBL531692 | 0.82 | PARP1 (0.54) | PARP1SMYD3PDE3BPDE3AMAOB | |
| SCHEMBL532865 | 0.80 | PARP1 (0.54) | PARP1SMYD3PDE3BPDE3AMAOB | |
| SCHEMBL531876 | 0.80 | PARP1 (0.68) | PARP1SMYD3PDE3BPDE3AHTR1A | |
| SCHEMBL6996778 | 0.79 | PARP1 (0.54) | PARP1 | |
| SCHEMBL7003692 | 0.78 | PARP1 (0.74) | PARP1SMYD3PDE3BPDE3AMAOB | |
| SCHEMBL12235342 | 0.77 | PARP1 (0.65) | PARP1SMYD3PDE3BPDE3A | |
| SCHEMBL5967448 | 0.77 | PARP1 (0.65) | PARP1SMYD3PDE3BPDE3A | |
| SCHEMBL5967473 | 0.77 | PARP1 (0.65) | PARP1SMYD3PDE3BPDE3A | |
| SCHEMBL5189907 | 0.76 | PARP1 (0.64) | PARP1SMYD3PDE3BPDE3AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669249-B2 | Poly (ADP-ribose) polymerase (PARP) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-11 | — | — | US | disclosed |
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-2415767-A1 | Poly (ADP-ribose) Polymerase (PARP) Inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2012-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094992-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885SMYD3 3712/4885PDE3B 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.